Buch, Englisch, 301 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 493 g
Buch, Englisch, 301 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 493 g
Reihe: Biotechnology Intelligence Unit
ISBN: 978-3-662-22117-4
Verlag: Springer
This book provides an up-to-date evaluation of clinical aspects of newly available "long-circulating liposome" formulations. Based on results from numerous clinical studies, the book describes the fundamentals of this new technology, discusses how it may influence the pharmacology of existing well-known agents reformulated in this manner, and elaborates on future expectations. It provides the practicing clinician - in particular, oncologists and critical care infectious disease physicians - with the tools needed to use these new formulations towards the best outcome for the patient.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
- Naturwissenschaften Biowissenschaften Zellbiologie
Weitere Infos & Material
1. Long Circulating Liposome Therapeutics: From Concept to Clinical Reality.- 2. Oncologic Agents in Sterically Stabilized Liposomes: Basic Considerations.- 3. Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations.- 4. Long Circulating Liposome-Encapsulated Tumor Necrosis Factor in the Treatment of Solid Tumors.- 5. Therapy of Human Carcinoma Xenografts with Doxorubicin Encapsulated in Sterically Stabilized Liposomes (DOXIL®): Efficacy and Safety Studies.- 6. Design and Development of Long Circulating Liposomal Daunorubicin for In Vivo Targeting of Solid Tumors: DaunoXome®.- 7. Enhancement of Doxorubicin by Encapsulation in Long circulating Thermosensitive Liposomes Combined with Local Hyperthermia.- 8. Liposomal Localization and Chemotherapy for AIDS-Related Kaposi’s Sarcoma.- 9. Pegylated-Liposomal Doxorubicin (Doxil®) in the Treatment of AIDS-Related Kaposi’s Sarcoma.- 10. DaunoXome® (Liposomal Daunorubicin) for First-Line Treatment of Advanced, HIV-Related Kaposi’s Sarcoma.- 11. Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors.- 12. Antibacterial Therapy with Sterically Stabilized Liposome Formulations.- 13. AmBisome®: Long Circulating Liposomal Formulation of Amphotericin B.- 14. Steric Stabilization of Liposomes Containing Amphotericin B: A Future Direction in Antifungal Therapy?.- 15. Clinical and Preclinical Studies with Low-Clearance Liposomal Amikacin (MiKasome®).- 16. Sterically Stabilized Liposomes to Image Infection and Inflammation.- 17. Long Circulating Liposomes for Diagnostic Imaging.- 18. Tumor Imaging with Long Circulating Liposomes.- 19. Antibody-Mediated Targeting of PEG-Coated Liposomes.- 20. Small Molecule Ligands for Targeting LongCirculating Liposomes.
